T1	p 173 238	patients with chronic heart failure after myocardial infarction .
T2	p 373 409	patients with heart failure ( HF ) .
T3	p 558 561	800
T4	p 570 637	) in patients with class II to IV HF and ejection fraction < 35 % .
T5	p 1484 1551	patients with chronic postinfarction cardiomyopathy , transcatheter
T6	p 1849 1895	HF patients with postinfarction cardiomyopathy
T7	i 127 148	myoblast implantation
T8	i 152 160	catheter
T9	i 312 356	transcatheter intramyocardial administration
T10	i 360 369	myoblasts
T11	i 441 459	placebo-controlled
T12	i 469 550	image-guided , catheter-based intramyocardial injection of placebo or myoblasts (
T13	i 994 1001	placebo
T14	i 1100 1110	amiodarone
T15	i 1164 1171	placebo
T16	i 1354 1361	placebo
T17	i 1570 1579	myoblasts
T18	o 81 114	safety and cardiovascular effects
T19	o 662 790	frequency of serious adverse events ( safety ) and changes in 6-minute walk test and Minnesota Living With HF score ( efficacy )
T20	o 947 964	numbers of events
T21	o 1053 1096	deaths . Ventricular tachycardia responsive
T22	o 1242 1264	in functional capacity
T23	o 1314 1318	walk
T24	o 1432 1463	Minnesota Living With HF scores